The numbers are staggering by any standard. A 133.7 percent gain in 30 days. A stock trading 524 percent above its 52-week low. A volatility reading of 517 percent that makes even the most seasoned traders blink twice. Moderna has delivered one of the most extraordinary momentum runs in recent S&P 500 history — and now Wall Street is arguing over whether the biotech’s spectacular ascent is justified or simply a case of the market getting carried away.
The Rally That Defies Conventional Metrics
Moderna’s shares currently trade at 120.80 euros, having pulled back 7.2 percent over the past week alone. The distance from the 200-day moving average stands at a remarkable 146 percent, while the stock’s 52-week low of 19.36 euros now sits a jaw-dropping 524 percent in the rearview mirror. The 30-day volatility figure of 517 percent underscores just how far the stock has detached from its historical trading range.
Yet the relative strength index sits at 60.4 — a reading that, despite the recent pullback, does not yet signal an acutely overbought condition. The technical picture suggests a stock in motion, but one where the direction of travel could shift violently in either direction.
The catalyst for this extraordinary move traces back roughly three weeks, when Merck and Moderna unveiled positive topline results from the Phase 3 INTerpath-001 trial. The study evaluated Intismeran (V940 or mRNA-4157), an mRNA-based individualized neoantigen therapy, in combination with Merck’s immunotherapy Keytruda as an adjuvant treatment for melanoma patients following surgery. The companies reported statistically significant improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone — the first combination regimen to achieve such results in this setting. Since that announcement, the stock has added another 5.7 percent.
Analysts Push Back on Valuation
The clinical progress is not in dispute. The question dividing the Street is whether the market’s response has been proportionate. On Thursday, Simon Baker of Rothschild & Co Redburn downgraded the stock from “Neutral” to “Sell,” acknowledging the melanoma data as “undoubtedly good” while arguing that the market’s reaction had overshot the mark. Baker raised his price target from 40 to 81 US dollars — a level that still sits well below where the shares trade.
That skepticism lands on a stock that has climbed 354 percent since the start of the year. In August, an interim readout from the melanoma study reportedly triggered a single-day surge of roughly 177 percent. The shares closed yesterday at 120.58 euros, leaving them about 19 percent below the 52-week high of 149.62 euros.
Should investors sell immediately? Or is it worth buying Moderna?
Not everyone shares Baker’s caution. Argus upgraded the stock to “Buy” in late August with a price target of 180 US dollars, underscoring the sharp divergence of opinion among analysts tracking the name.
The Financial Foundation Under the Oncology Story
Beyond the oncology pipeline, Moderna’s traditional vaccines business continues to provide a revenue base. The company received FDA approval in late August for its updated COVID-19 vaccines for the 2026-2027 season. Around the same time, management moved to shore up the balance sheet, completing the placement of a 2.6 billion US dollar convertible bond roughly a week ago — a move that has coincided with a 7.4 percent decline in the share price since.
The net proceeds from that private placement are earmarked for oncology growth initiatives and debt repayment. The financing arrives against a backdrop of modest current revenues: the company reported second-quarter sales of 0.1 billion US dollars and a GAAP net loss of 0.8 billion US dollars. Management nonetheless reaffirmed its target of up to 10 percent revenue growth for fiscal 2026.
A Momentum Leader With a Split Personality
Moderna’s position at the top of the S&P 500 momentum ranking sets it apart from the other names on that list — SANDISK, Marathon Petroleum, Salesforce, and Valero Energy — which have posted 30-day gains ranging from 21.9 percent to 42.1 percent. Where those stocks reflect operational strength in energy markets or a storage-chip supply squeeze, Moderna’s move is a bet on a pipeline story that has yet to translate into meaningful revenue.
The tension is palpable: clinical milestones continue to accumulate, the convertible raise provides financial runway, and the FDA approval keeps the vaccines franchise alive. But with the stock trading at levels that imply enormous expectations, the question of whether the fundamental story can catch up to the valuation — or whether the valuation will simply come down to meet the fundamentals — remains very much open. The 7.2 percent weekly pullback and the analyst downgrade suggest the market is already beginning to wrestle with that question.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from September 9 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 9.
Moderna: Buy or sell? Read more here...
